Patent SG-11201809680Q-A (SG)
Title: Anticancer compositions
Inventor: BERTELS JOHNY
IPC: A61P35/00
Filed: 2017-05-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) ill Hu omit DID HOHOM 00110 EMO 011 (10) International Publication Number WO 2017/209939 Al WIPO I PCT (51) International Patent Classification: A61K 31/58 (2006.01) A61K 9/20 (2006.01) A61K 31/4439 (2006.01) A61P 35/00 (2006.01) A61K 9/14 (2006.01) A61K 31/573 (2006.01) A61K 9/16 (2006.01) (21) International Application Number: PCT/US2017/032815 (22) International Filing Date: 16 May 2017 (16.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16172968.6 03 June 2016 (03.06.2016) EP (71) Applicant: ARAGON PHARMACEUTICALS, INC. [US/US]; 12780 El Camino Real, San Diego, California 92130 (US). (72) Inventors: BERTELS, Johny; Turnhoutseweg 30, 2340 Beerse (BE). MENSCH, Jurgen; Turnhoutseweg 30, 2340 Beerse (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: ANTICANCER COMPOSITIONS (57) : The present invention concerns pharmaceutical formulations of abiraterone actetate and ARN-509, which can be ad- ministered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMCAS, a poly(meth)acrylate copolymer, and mixtures thereof. In one aspect, these formulations comprise a granulate of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMC AS, a poly(meth)acrylate copolymer, and mixtures thereof.